AME What we don't know is how many subjects in the AME study had elevated liver enzyme tests beside the two which had the 500% above normal and triggered the Health Canada suspension.
It would take some risk-taking on Health Canada's part to give the go-ahead for its lead compound ATB-346 - if there were elevated numbers all-over-the-place with other patients. Does anyone actually know what the other numbers were? Were they all between 300 and 400% above normal or 10 to 20% above normal? Big difference.
If we don't know the other numbers - it is a very important unknown.
If you were a Health Canada employee you would be strictly walking the safety-line even if it meant that ATB-386 gets "re-formulated". You can bet that Health Canada will be in full CMA mode, now that they have been pulled into this. Of course they were always indirectly involved hence the automatic suspension.
Antibe could say it was going to focus on its other compounds in the pipeline and that they were still in discussions with potential a partners going forward - that does not mean jack. I'd say that too. That's expected. If that is what the release says then I think this will be .50 and lower instantly. The company can coast comfortably and pudder with rats "adding-value" by exploring other compounds for this-and-that with the cash they have - they have zero pressure. They can slow down the cash burn and take home cheques for years - they got the money...they have control of the company, feet up.
Obviously - I could be wrong - Monday they could announce the suspension lifted and resumption, and they have new patent protection applications, potential new drugs to look at. etc... etc...and they are in discussions with potential partners....